On August 10, 2026, a new publication regarding difelikefalin appeared in the journal Advances in Therapy. The publication is titled "Difelikefalin Treatment in Chronic Kidney Disease-Associated Pruritus: Modelling Infection-Related Hospitalisation Cost Offsets Using Trial and Real-World Data Across Seven European Countries."
The publication is indexed under PubMed ID 42573951. It addresses difelikefalin in the context of chronic kidney disease-associated pruritus. According to its title, the work involves modelling of infection-related hospitalisation cost offsets. This modelling reportedly draws on both trial data and real-world data. The scope of the analysis spans seven European countries, as stated in the title.
This item is recorded as a publication event rather than a clinical trial update or a regulatory action. No results, conclusions, or findings from the publication are described here beyond what is stated in its title. No efficacy or safety outcomes are reported in this brief. Readers seeking the full content, methodology, and any reported results should consult the publication directly through the provided link.
Difelikefalin is noted as an approved compound in the data associated with this event. For additional background on this compound, readers can consult the compound overview.